Manhattan Scientifics Stock Trades at Penny Levels Amid Volume Surge

Manhattan Scientifics, Inc. (MHTX) is trading at extreme penny levels on the PNK exchange, with MHTX stock showing a dramatic 126,564% relative volume spike compared to its 36-share daily average. The healthcare nano-technology incubator, based in New York, saw trading volume reach 4.56 million shares on May 21, 2026. MHTX stock trades well below its 50-day and 200-day moving averages at $0.00002 per share. This penny stock represents one of the market’s most distressed healthcare plays.

MHTX Stock Volume Explosion Signals Extreme Distress

MHTX stock experienced an extraordinary volume event, with 4.56 million shares traded against a typical daily average of just 36 shares. This represents a relative volume of 126,564%, one of the most extreme spikes possible in penny stock trading. The volume surge occurred with zero price movement, suggesting forced liquidation or institutional exit activity rather than organic buying interest.

Trading at $0.00002 per share, MHTX stock has collapsed 80% over the past year and 99.99% from its all-time highs. The stock trades below both its 50-day average of $0.0000936 and 200-day average of $0.0000984. Day trading range was tight at $0.00002 to $0.0001, reflecting minimal liquidity and extreme volatility typical of penny stocks in distress.

Manhattan Scientifics Financial Metrics Show Severe Deterioration

Manhattan Scientifics reports a market cap of just $11,186 with 559.28 million shares outstanding, creating massive dilution. The company generated zero revenue in trailing twelve months while posting a net loss of $0.01 per share. Working capital stands at negative $2.05 million, indicating the company cannot cover short-term obligations.

Key financial ratios paint a dire picture: current ratio of 0.033, negative book value per share of negative $0.0032, and negative return on assets of negative 3.69%. The company holds only $0.00012 per share in cash. Enterprise value sits at $4,186 against a market cap of $11,186, suggesting minimal tangible assets. Track MHTX on Meyka for real-time updates on this distressed healthcare play.

Technical Indicators Confirm Severe Weakness in MHTX Stock

Technical analysis reveals overwhelming bearish signals across all major indicators. The Relative Strength Index (RSI) sits at 41.54, showing weakness without oversold conditions. The Money Flow Index (MFI) reads 87.98, indicating overbought conditions despite the stock’s collapse, suggesting forced buying from short covering or algorithmic rebalancing.

The Rate of Change (ROC) shows negative 80%, confirming severe downward momentum. Williams %R at negative 80.81 signals extreme weakness. Moving average envelope slope of negative 3.89 indicates accelerating downtrend. Average True Range (ATR) near zero reflects minimal price movement capability. These indicators collectively suggest MHTX stock lacks institutional support and faces potential delisting risk.

Manhattan Scientifics Nano-Tech Focus Offers Limited Near-Term Catalysts

Manhattan Scientifics operates as a technology incubator focused on nano-technologies and nano-medicine development. The company employs just one full-time employee and maintains minimal operational activity. CEO Emmanuel Tsoupanarias leads the organization from its New York headquarters at 244 Fifth Avenue.

The next earnings announcement is scheduled for August 22, 2025. With zero revenue generation and mounting losses, the company faces existential challenges. The nano-tech sector remains speculative, and MHTX stock’s extreme dilution and negative equity make recovery unlikely without major capital injection or strategic acquisition. Investors should treat this as a highly speculative, distressed security.

Final Thoughts

MHTX stock represents an extreme penny stock situation with a massive volume spike, severe financial deterioration, and technical weakness across all indicators. Trading at $0.00002 with a market cap of just $11,186, Manhattan Scientifics faces potential delisting and has zero near-term catalysts. The 126,564% relative volume spike combined with negative equity, zero revenue, and one employee suggests institutional exit activity. Investors should avoid MHTX stock unless they understand penny stock risks and can afford total loss. The company’s nano-tech focus offers no near-term value creation.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.